Novavax, Inc. (NASDAQ:NVAX) shares have been given a 1 rating by analysts surveyed by Zacks Investment Research. Sell-side firms often use different terminology for their ratings so this scale provides a simple consensus number. The ratings are calculated on a 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. When analysts were polled three months ago, the stock had an average rating of 1.
Sell-Side brokerage firms have a price target of $10.883 on shares of Novavax, Inc. (NASDAQ:NVAX). This is based on analysts one year projections on the stock. The most bearish analyst outlook has a price target of $10, while the most aggressive firm sees the stock reaching $12 within the year.
Investors will be marking 2015-08-05 on their calendars as this is when Novavax, Inc. is slated to next issue their quarterly earnings. Analysts surveyed by Zacks are anticipating earnings of $-0.09 per share for the period closing on 2015-06-30. This is the Zacks consensus number based on 6 Wall Street analysts covering the equity. Looking ahead longer term, the Sell-Siders have tagged the stock with expected earnings of $N/A. This is the best estimate for both sales and earnings over the next 3-5 years, as calculated by Zacks.
For the most recent quarter, Novavax, Inc. announced earnings per share of $-0.1 for the fiscal period ending on 2015-03-31. The actual number was $0.01 away from what analysts had expected, or a 9.09% surprise factor.
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company’s vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...